Clinical Trial

A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 29, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase III clinical trial is designed to assess the efficacy and safety of Anaprazole 60 mg once daily (QD) administered over a period of up to 8 weeks, compared with Rabeprazole 20 mg QD, in patients with reflux esophagitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-30.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT07010107
Lead Sponsor Xuanzhu Biopharmaceutical Co., Ltd.
Conditions Reflux Esophagitis (RE)
Enrollment 500 participants
Start Date 2025-07-30
Primary Completion 2026-04 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-29